问象观察站/今日概览

Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis

Recursion official investor newsroom · Indexed industry source record · Source published: Wed Nov 18 2026 09:59:32 GMT+0000 (Coordinated Universal Time) · Indexed here: Wed Nov 18 2026 10:08:16 GMT+0000 (Coordinated Universal Time)

Original sources

Saved source excerpt

Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis November 18, 2026 at 4:59 AM EST PDF Version REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through

This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.

How to assess model and industry evidence →

The interface and original reader guides use the selected language. Source titles, excerpts, event summaries, and evidence quotations retain their original language.

访问统计与隐私说明

本站用第一方统计了解哪些页面、原始出处与连接功能受到关注。统计记录仅含允许的页面路径、动作标识和来源域名,不含搜索词、表单内容、完整链接或原始 IP。

匿名会话标识仅保存在当前标签页,30 分钟没有活动后更新,不代表独立人数。浏览器的 Do Not Track(DNT)或 Global Privacy Control(GPC)信号会停止网页事件采集;管理页面和管理操作不采集。

MCP 使用量由服务端实际执行的工具记录,网页复制按钮点击不会算作工具调用,也不证明复制成功。测试流量与按浏览器标识识别的自动化访问从网页统计排除,识别可能存在误差;统计事件保留 90 天。